Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Epidemiologic Evaluation and Clinical Outcomes for HER2-negative Metastatic Breast Cancer (MBC) Patients With Germline BRCA1 and 2 Pathogenic Mutation in Korea

NCT04368442 is registered in ClinicalTrials.gov with Samsung Medical Center as lead sponsor.

NCT NCT04368442
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04368442 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Epidemiologic Evaluation and Clinical Outcomes for HER2-negative Metastatic Breast Cancer (MBC) Patients With Germline BRCA1 and 2 Pathogenic Mutation in Korea
Lead sponsor
Samsung Medical Center
Phase
Observational
Overall status
Unknown status
Start date
October 17, 2019
Completion date
December 31, 2021
Enrollment
583 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer metastatic